Hoth Therapeutics Announces Major Advancements For HT-KIT, Filing Amended Claims For Enhanced IP Protection And Initiating GLP-Compliant Preclinical Toxicity Study To Support Regulatory Filings For Its ASO Cancer Drug Candidate Targeting Allergic Inflamma